← back to search

Weifang Yu

First Affiliated Hospital of Hebei Medical University ·
Area of research
Molecular Biology · Cancer Research
Research interest
Research interests include Cancer-related molecular mechanisms research, Cancer-related gene regulation, RNA modifications and cancer, and MicroRNA in disease regulation.
h-index
15
citations
587
works
43
NIH funding
primary concept
email

Recent publications

A comparison of diagnostic and therapeutic approaches for Mycoplasma pneumoniae pneumonia in children and adults, during the post-COVID-19 pandemic era
European Journal of Clinical Microbiology & Infectious Diseases 2025cited by 3position: middledoi
TMEM65 promotes gastric tumorigenesis by targeting YWHAZ to activate PI3K-Akt-mTOR pathway and is a therapeutic target
Oncogene 2024cited by 16position: middledoi
Downregulation of Roundabout guidance receptor 2 suppresses hepatocellular carcinoma progression by interacting with Y-box binding protein 1
Scientific Reports 2024cited by 1position: middledoi
YTHDF1 Facilitates Lung Adenocarcinoma Progression via Promotion of EEF1G Translation in a m6A-Dependent Manner
bioRxiv (Cold Spring Harbor Laboratory) 2024cited by 0position: middledoi
Integrin beta 4 promotes colorectal cancer progression by upregulating Ezrin and activating the Wnt/β-catenin signaling pathway
bioRxiv (Cold Spring Harbor Laboratory) 2024cited by 0position: lastdoi
Clinical characteristics and high risk factors of patients with Omicron variant strain infection in Hebei, China
Frontiers in Cellular and Infection Microbiology 2023cited by 4position: lastdoi
miR-17-5p promotes the invasion and migration of colorectal cancer by regulating HSPB2
Journal of Cancer 2022cited by 29position: firstdoi
IDDF2022-ABS-0237 TMEM65 interacts with YWHAZ to promote gastric cancer progression
2022cited by 0position: middledoi
ITGB4 as a novel serum diagnosis biomarker and potential therapeutic target for colorectal cancer
Cancer Medicine 2021cited by 23position: middledoi
Two New Methods of Supine Venographically Guided Popliteal Vein Puncture: A Retrospective Study
European Journal of Vascular and Endovascular Surgery 2021cited by 4position: middledoi
miR-17-5p promotes the invasion and migration of colorectal cancer by regulating HSPB2
Research Square 2021cited by 2position: firstdoi
The inhibitory effects of probiotics on colon cancer cells: in vitro and in vivo studies
Journal of Gastrointestinal Oncology 2020cited by 64position: middledoi
<i>TRIM67</i> inhibits tumor proliferation and metastasis by mediating <i>MAPK11</i> in Colorectal Cancer
Journal of Cancer 2020cited by 32position: lastdoi
Thapsigargin promotes colorectal cancer cell migration through upregulation of lncRNA MALAT1
Oncology Reports 2020cited by 30position: middledoi
The Construction and Comprehensive Prognostic Analysis of the LncRNA-Associated Competitive Endogenous RNAs Network in Colorectal Cancer
Frontiers in Genetics 2020cited by 11position: middledoi
Cyto‑biological effects of microRNA‑424‑5p on human colorectal cancer cells
Oncology Letters 2020cited by 8position: lastdoi
Reduced Kiss‑1 expression is associated with clinical aggressive feature of gastric cancer patients and promotes migration and invasion in gastric cancer cells
Oncology Reports 2020cited by 7position: lastdoi
ITGB4 is a novel prognostic factor in colon cancer
Journal of Cancer 2019cited by 69position: middledoi
Evaluation of the diagnostic value of peripheral BDNF levels for Alzheimer’s disease and mild cognitive impairment: results of a meta-analysis
International Journal of Neuroscience 2019cited by 39position: middledoi
Application value of CyTOF 2 mass cytometer technology at single-cell level in human gastric cancer cells
Experimental Cell Research 2019cited by 8position: lastdoi
Prediction of Overall Survival for Colorectal Cancer: Establishment and Validation of a Prognostic Nomogram Based on a Competitive Endogenous RNAs Network Analysis
SSRN Electronic Journal 2019cited by 0position: middledoi
Dapper homolog 1 alpha suppresses metastasis ability of gastric cancer through inhibiting planar cell polarity pathway
Oncotarget 2016cited by 11position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Zengren Zhao · Hebei Medical University14 papers (2016–2024)Xia Jiang · Xuzhou Medical College8 papers (2019–2021)Guiqi Wang · Hebei Medical University8 papers (2016–2020)Shuangshuang Han · Nankai University6 papers (2019–2024)Congjie Zhai · First Affiliated Hospital of Hebei Medical University6 papers (2019–2025)Mingda Xuan · Hebei Medical University6 papers (2020–2024)Yuegeng Liu · Hebei Medical University4 papers (2016–2020)Hongjuan Yue · Hebei Medical University3 papers (2023–2025)Qihong Sheng · Hebei Medical University3 papers (2023–2025)Shihao Chen · Nanjing Tech University3 papers (2020–2020)Fangjian Shang · Hebei Medical University3 papers (2020–2020)Jia Wang · Sun Yat-sen University3 papers (2023–2025)Xiaojia Jiang · People's Hospital of Cangzhou2 papers (2022–2024)Jia Wang · China Agricultural University2 papers (2021–2022)Xian Gao · Hebei Medical University2 papers (2020–2021)Shang Guo · Shanghai Jiao Tong University2 papers (2020–2022)Xiaojing Jin · Wenzhou Medical University2 papers (2019–2020)Jia Wang · Qingdao University2 papers (2021–2024)Yingfu Zhang · Hebei Medical University2 papers (2021–2022)Dongyun Li · University of Jinan2 papers (2020–2020)